Survival benefits of different antiadrenergic interventions in pressure overload left ventricular hypertrophy/failure

Hypertension. 2006 Jul;48(1):93-7. doi: 10.1161/01.HYP.0000226859.42064.ea. Epub 2006 Jun 5.

Abstract

We observed previously that in rats with aortic banding (Bd), development of left ventricular (LV) hypertrophy is opposed by beta-blockade, whereas interventions interfering with alpha-adrenoceptor function also inhibit interstitial fibrosis. To assess whether these differential structural effects do translate into different effects on LV function and on heart failure mortality, Bd or sham Bd 8-week-old rats were randomized to vehicle treatment (Vh), chemical sympathectomy ([Sx] 6-hydroxydopamine, 150 mg/kg IP twice a week), beta-adrenoceptor blockade (propranolol [Pro], 40 mg/kg per day PO), or alpha-adrenoceptor blockade (doxazosin [Dox], 5 mg/kg per day PO). After monitoring survival for 10 weeks, the survivors were anesthetized to undergo echocardiography and intraarterial blood pressure measurement. Bd-Vh rats showed increased LV and lung weights, as well as LV dilation, depressed endocardial and midwall fractional shortening and a restrictive transmitral diastolic flow velocity pattern. Compared with Bd-Vh rats, all of the actively treated Bd rats showed less LV hypertrophy, LV dilation, and lung congestion but no less depression of midwall fractional shortening. In contrast, Sx and Dox but not Pro treatment were also associated with lesser degrees of diastolic dysfunction and, even more importantly, with a striking increase in survival (sham banded rats, 100%; Bd-Vh, 40%; Bd-Pro, 51%; Bd-Sx, 83%; and Bd-Dox, 82%). Although Pro, Sx, and Dox provide similar midterm protection from development of LV hypertrophy and dysfunction and from circulatory congestion, only Sx and Dox favorably affected mortality. These findings indicate that in the aortic banding rat model, alpha-adrenoceptors are importantly involved in the pathogenesis of cardiovascular deterioration and disease progression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Antagonists / therapeutic use*
  • Adrenergic beta-Antagonists / therapeutic use*
  • Animals
  • Aorta, Abdominal / surgery
  • Blood Pressure
  • Doxazosin / therapeutic use
  • Heart Failure / drug therapy
  • Heart Failure / therapy
  • Heart Rate
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Hypertension / therapy
  • Hypertrophy, Left Ventricular / etiology
  • Hypertrophy, Left Ventricular / prevention & control*
  • Male
  • Oxidopamine
  • Propranolol / therapeutic use
  • Rats
  • Rats, Sprague-Dawley
  • Sympathectomy, Chemical*

Substances

  • Adrenergic alpha-Antagonists
  • Adrenergic beta-Antagonists
  • Oxidopamine
  • Propranolol
  • Doxazosin